IRMD — IRadimed Corporation

IRADIMED CORPORATION Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $22.7 million, a 17% increase from Q4 2024 ($19.4 million).
• Full Year Revenue: $83.8 million, up 14% year-over-year from $73.2 million.
• GAAP Diluted EPS: $0.50 for Q4 (up 25%); $1.75 for the full year (up 17%).
• Non-GAAP Diluted EPS: $0.54 for Q4 (up 23%); $1.93 for the full year (up 16%).
• Gross Margin: Approximately 75% for Q4; 77% for the full year.
• Operating Income: $7.1 million for Q4; $26.1 million for the full year.
• Cash and Cash Equivalents: $51.2 million at year-end; cash flow from operations was $5.9 million for Q4 and $24.9 million for the full year.

2. Strategic Updates and Business Highlights

• Achieved 18 consecutive quarters of record revenue.
• Strong growth in MRI-compatible infusion pump systems ($9.1 million, up 20% year-over-year) and patient vital signs monitoring systems ($7.1 million, up 7.5%).
• Successful initial order of 23 new 3870 MR IV pump systems, with positive feedback leading to additional orders.
• Anticipated 10% to 14% increase in average selling price (ASP) for the new 3870 pump, with a focus on replacing older models.
• Targeting to sell over 2,000 3870 pump channels annually, aiming for a $100 million-plus revenue run rate in 2026.

3. Forward Guidance and Outlook

• Expect continued revenue growth in the first half of 2026, driven by MRI monitoring and existing pump backlog.
• Anticipate significant bookings for the 3870 systems starting in Q2 2026, with initial shipments planned for April.
• Projecting gross margins to potentially improve in the second half of 2026 as production scales and ASP increases.

4. Bad News, Challenges, or Points of Concern

• Transitioning from the older 3860 model to the new 3870 may pose inventory management challenges.
• Regulatory approvals for the 3870 in Europe and Japan are expected to take time, with CE marking anticipated by the end of 2026 and Japan clearance not expected until summer 2027.
• Potential risks associated with market acceptance of the new product and competition in the medical device space.

5. Notable Q&A Insights

• Positive feedback from initial users of the 3870 pump, indicating strong market interest and excitement.
• CFO indicated that gross margins may remain stable initially but could improve with higher volumes and ASP in the latter half of the year.
• R&D is already focused on the next-generation MRI monitor, expected to launch in 2028.
• Management is closely monitoring inventory levels of the 3860 to ensure a smooth transition to the 3870.

This summary encapsulates IRADIMED's strong financial performance, strategic initiatives, and outlook while also acknowledging potential challenges and market dynamics.